Novo's Amylin Injectable Cagrilintide Hits 11.8% Weight Reduction in Phase III Trial US$ 21.01 Min. order: 1 piece ★★★★★ 4.2 (66 reviews) Sold : Login>>
Novo Nordisk presents phase 3 data for next-generation amylin cagrilintide, leading to advancement into dedicated clinical programme US$ 27.05 Min. order: 1 piece ★★★★★ 4.2 (261 reviews) Sold : Login>>
Novo Nordisk advances obesity candidate to late-stage program after weight loss of less than 12% US$ 23.78 Min. order: 1 piece ★★★★★ 4.2 (217 reviews) Sold : Login>>